Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals is set to showcase its innovative drug delivery solutions at the American College of Gastroenterology Annual Scientific Meeting 2024 with two awarded posters. These presentations highlight the company’s promising EP-104GI therapy for eosinophilic esophagitis, underscoring Eupraxia’s potential in addressing unmet medical needs. Investors may want to watch Eupraxia’s progression in the biotech space as it continues to develop its pipeline of advanced treatments.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
